Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson
{"title":"活细胞青霉素结合蛋白的kinact/KI值测定。","authors":"Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson","doi":"10.1021/acsinfecdis.4c00370","DOIUrl":null,"url":null,"abstract":"<p><p>Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC<sub>50</sub> values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> values are typically obtained from <i>in vitro</i> assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> assay to define inhibitor potency for the PBPs in <i>Streptococcus pneumoniae</i> using the fluorescent, activity-based probe, Bocillin-FL. Our results align with <i>in vitro k</i><sub>inact</sub>/<i>K</i><sub>I</sub> data and show a comparable relationship to previously established IC<sub>50</sub> values. These results support the validity of our <i>in vivo k</i><sub>inact</sub>/<i>K</i><sub>I</sub> method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":"4137-4145"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984511/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> Value Determination for Penicillin-Binding Proteins in Live Cells.\",\"authors\":\"Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson\",\"doi\":\"10.1021/acsinfecdis.4c00370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC<sub>50</sub> values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> values are typically obtained from <i>in vitro</i> assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> assay to define inhibitor potency for the PBPs in <i>Streptococcus pneumoniae</i> using the fluorescent, activity-based probe, Bocillin-FL. Our results align with <i>in vitro k</i><sub>inact</sub>/<i>K</i><sub>I</sub> data and show a comparable relationship to previously established IC<sub>50</sub> values. These results support the validity of our <i>in vivo k</i><sub>inact</sub>/<i>K</i><sub>I</sub> method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":\" \",\"pages\":\"4137-4145\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984511/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acsinfecdis.4c00370\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00370","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
kinact/KI Value Determination for Penicillin-Binding Proteins in Live Cells.
Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC50 values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, kinact/KI, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, kinact/KI values are typically obtained from in vitro assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell kinact/KI assay to define inhibitor potency for the PBPs in Streptococcus pneumoniae using the fluorescent, activity-based probe, Bocillin-FL. Our results align with in vitro kinact/KI data and show a comparable relationship to previously established IC50 values. These results support the validity of our in vivo kinact/KI method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.